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A rapid and increasing spread of COVID-19 pandemic disease has been perceived
worldwide in 2020. The current COVID-19 disease outbreak is due to the spread of
SARS-CoV-2. SARS-CoV-2 is a new strain of coronavirus that has spike protein on the
envelope. The spike protein of the virus binds with the ACE-2 receptor of the human lungs
surface for entering into the host. Therefore, the blocking of viral entry into the host by
targeting the spike protein has been suggested to be a valid strategy to treat COVID-19.
The patients of COVID-19 were found to be asymptomatic, cold, mild to severe respiratory
illness, and leading to death. The severe illness has been noted mainly in old age people,
cardiovascular disease patients, and respiratory disease patients. However, the long-term
health effects due to COVID-19 are not yet known. Recently, the vaccines were authorized
to protect from COVID-19. However, the researchers have put an effort to discover
suitable targets and newer medications in the form of small molecules or peptides, based
on in-silico methods and synthetic approaches. This manuscript describes the current
perspectives of the causative agent, diagnostic procedure, therapeutic targets, treatment,
clinical trials, and development of potential clinical candidates of COVID-19. The study will
be useful to identify the potential newer medications for the treatment of COVID-19.
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INTRODUCTION
Severe Acute Respiratory Syndrome Coronavirus-2
The virus is an intracellular parasite that affects the susceptible and permissive cells to complete its
life cycle. Coronavirus belongs to a large family of zoonotic viruses and mainly affects mammals and
birds (Bande et al., 2015; Lee, 2015). A large trimeric crown-like complex of the virus in microscopic
observation has given the name, i.e., corona. The genomic structure of coronavirus categorizes them
into four subgroups (alpha, beta, gamma, and delta). The alpha and beta subgroups of coronavirus
infect humans (Rabi et al., 2020). Coronavirus is the beta subgroup in the family of Coronaviridae
(Zheng, 2020). In humans, coronavirus causes a respiratory illness from mild cold to severe
respiratory diseases. Six strains of coronavirus were known from the past decade. Recently, a
novel coronavirus now named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
emerged in December-2019. SARS-CoV-2 is an enveloped, positive-sense single-stranded RNA virus
with 30,000 base lengths. It was likely to be originated from the bat and is genetically related to other
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coronaviruses. The new strain of coronavirus (SARS-CoV-2)
differs from the previous strains of coronavirus with the
critical amino acid residues at the receptor-binding domain
(RBD). These residues help the virus to interact with the host
organism.
Coronavirus Disease-2019
The respiratory illness associated with SARS-CoV-2 was
named coronavirus disease-2019 (COVID-19). Then, the
new strain of severe acute respiratory syndrome coronavirus
(SARS-nCoV) was designated as a causative agent for COVID-
19 by World Health Organization (Chen et al., 2020a; Imai
et al., 2020). COVID-19 spread among the population rapidly
in 2020 and has threatened public health extremely. The
outbreak of COVID-19 has begun in Wuhan city, China
and it has infected around 163,312,429 people worldwide
(Imai et al., 2020). Till now, around 3,386,825 deaths were
documented globally [Updated on 18th May-2021].
United States of America, Brazil, China, Italy, Iran, India
are the most affected countries (Centers for Disease Control
and Prevention, 2020; Grasselli et al., 2020; Kim et al., 2020;
Zhu et al., 2020a). Due to the increase in the spread of disease,
the public health emergency was announced by the World
Health Organization. COVID-19 has been viewed as the worst
health crisis of the current century.
Symptoms
COVID-19 is one of the types of respiratory diseases and it is
caused by SARS-CoV-2. The pathogenicity of SARS-CoV-2 is
similar to that of other severe acute respiratory syndrome
coronavirus (SARS-CoV) (Kuba et al., 2005; Rabi et al., 2020).
However, SARS-CoV-2 is structurally different in surface
proteins and viral load kinetics (Cevik et al., 2020). Moreover,
the specific symptoms related to COVID-19 are not known. The
nasal discharge and saliva from the infected person spread this
virus infection from human to human. Respiratory droplets,
direct contact with the infected patients also transmit this
virus (Harrison et al., 2020). SARS-CoV-2 is known to cause
illness of varying severity, ranging from mild to severe, and even
death by affecting the respiratory organs. The symptom may be
observed within 2–14 days after exposure to the virus (Li et al.,
2020a). The average incubation period for the development of the
disease is 5 days. The initial phase of COVID-19 shows flu-like
symptoms, and it is progressed into organ dysfunction at the later
phase (Harrison et al., 2020). Fever, dry cough, cough, sore throat,
shortness of breath, malaise, respiratory distress, diarrhea, and
taste disturbances are the common symptoms of COVID-19 (Jin
et al., 2020a). Lymphopenia, thrombocytopenia, dyspnea, septic
shock, etc., are symptoms observed at the severe stage of COVID-
19 (Centers for Disease Control and Prevention, 2020; Harrison
et al., 2020). The respiratory illness, neurological problems,
vascular to renal deficiency, the autoimmune response was
also observed at the various stages of infection. The
complication increases mostly among the older people, the
patients associated with cardiovascular disease, diabetes,
chronic respiratory problems, cancer, etc., (Grasselli et al.,
2020; Wang et al., 2020a).
Diagnostic Procedure for COVID-19
The increased level of C-reactive protein, lactate dehydrogenase,
or both can be observed after 3–6 days of exposure to the virus
(Poggiali et al., 2020). The diagnosis of COVID-19 is based on
real-time PCR (Jawerth, 2020), Sanger sequencing (Lee et al.,
2013; Yu et al., 2020a), NGS genome analysis (Chiara et al., 2020),
nucleic acid amplification (Mustafa Hellou et al., 2021),
microarray-based assay techniques (Hua et al., 2015) etc.,
Corman et al developed a diagnostic workflow for the
detection of a novel coronavirus, i.e., SARS-CoV-2 (Corman
et al., 2020). The other diagnostic methods like colorimetric
assay based on gold nanoparticles and COVID-19 IgG rapid
test kit are also employed for the diagnosis of SARS-CoV-2
(Amawi et al., 2020; Corman et al., 2020; Okamaoto et al., 2020).
The diagnostic methods for the detection of SARS-CoV-2 may
be classed into five groups, 1) RT-PCR: RT-PCR is an
experimental-based method for the detection of genomic RNA.
The process of RT-PCR uses an enzyme reverse transcriptase for
the conversion of RNA into complementary DNA, followed by
the amplification of cDNA. The procedure uses the respiratory
samples for diagnosis. It involves reaction primers and genetically
engineered probes for detection (Corman et al., 2020). 2) LAMP/
RT-LAMP: The loop-mediated amplification (LAMP) technique
involves the amplification of nucleic acid at a single temperature
(60–65°C). It is an alternative diagnostic method to PCR for the
detection of SARS-CoV-2. The diagnosis can be employed on
crude samples with a high amplification rate (109 copies of the
gene within an hour) (Yüce et al., 2021). 3) CRISPR technique:
CRISPR amplifies the nucleic acid of RNA sequence via cas
variant (Cas13 for SHERLOCK, Cas12a for DETECTR). The
method is rapid and specific (Mohamadian et al., 2021). 4) Chest-
CT scan: A chest CT scan requires a specialized instrument to
conduct the test. Ground-glass opacities, vascular enhancement
fibrosis, and interlobular septal thickening were identified as
characteristic features in the diagnosis (Hani et al., 2020). 5)
Serology testing (antibody detection): An immune system
produces antibodies in response to the antigen. IgA, IgD, IgE,
IgG, and IgM are the antibodies and IgM is the antibody
produced at the time of infection, IgG is abundant in the
blood. These antibodies neutralize antigens by binding to
them. The antibody detection tests estimate the concentration
of IgM and IgG levels in the blood sample to diagnose the patients
(Jacofsky et al., 2020).
THE TREATMENT FOR COVID-19
INFECTION
An ideal strategy to stop the spread of COVID-19 involves the
blocking of the cause of infection rather than treating the disease
symptoms. The therapeutic strategies for the treatment of SARS-
CoV-2 may be classified into the following categories 1)
inhibition of viral binding to the host 2) inhibition of viral
replication 3) restoring the host’s immunity. The identification
of specific drugs based on the above-mentioned classifications
would help in the management of COVID-19 infection. However,
no selective drugs have been discovered/approved by the Food
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and Drug Administration (FDA) for the treatment of COVID-19.
At present, few vaccines were approved and many others are
under clinical trials to treat COVID-19 (Borah et al., 2021). An
attempt to repurpose the existing and clinically approved drugs is
also in progress (Amawi et al., 2020).
Vaccination
Sputnik V is the first vaccine against COVID-19 and it was
approved in Aug-2020. The vaccine was developed based on two
human adenovirus vectors. Adenovirus is a common cold virus
and the encoding gene of the spike protein of SARS-CoV-2
generates immunity. The adenovirus type 26 and type 5 are
used as vectors to develop the vaccine. Adenovirus type 26
based vaccine is administered on the first day of vaccination
and type 5 is administered to boost the immunity on the 21st day.
At the time of approval of Sputnik V in Russia, it was declared
safe. However, it was also commented as a premature vaccine
since the phase-3 trial was not completed. Nevertheless, phase-1
and phase-2 studies have reported 91.6% efficacy of the vaccine
and the study has not shown any unusual side effects. Then,
Sputnik V has been launched and reached 59 other countries on
Apr-2021 (Logunov et al., 2020).
Convalescent Plasma Therapy
Plasma is the liquid component of blood and it is yellowish in
appearance. The plasma separated from blood contains minerals,
proteins, and antibodies. The COVID-19 patients recovered from
the infection may have developed antibodies to combat COVID-19.
Therefore, this approach transfuses these antibodies into COVID-19
patients. The transfused antibody neutralizes foreign objects like
SARS-CoV-2. Convalescent plasma therapy is employed as a
treatment procedure for critically ill patients of COVID-19. It
provides passive immunity to the COVID-19 patients to recover.
Convalescent plasma therapy is effective in the absence of antiviral
agents or vaccines. It has been approved by FDA in the United States
for the management of COVID-19 (Rojas et al., 2020).
The Chinese System of Medicine
Chinese traditional medicine provides ShuFengJieDu capsules
and Lianhua Qingwen capsules for the treatment of COVID-19.
The clinical trial data to ensure the safety and efficacy of these
Chinese traditional medicines against COVID-19 is not available.
However, the therapeutic significance of ShuFengJieDu capsules
against respiratory tract infection, and pulmonary infection is
known (Chen et al., 2020b; Ji et al., 2020). ShuFengJieDu capsule
consists of polygonum cuspidatum, radix isatidis, forsythia,
verbena, bupleurum, radix, and reed root. It has shown broad-
spectrum antiviral activity against several viruses including
influenza-A virus H1N1 and adenovirus (Wang et al., 2020b).
Lianhua Qingwen capsule has been used for the treatment of viral
influenza, and SARS. The various therapeutic actions of Lianhua
Qingwen are antiviral activity, anti-inflammatory activity, and
immune system-related functions (Li et al., 2020b). Quercetin,
luteolin oxalin, and kaempferol are active ingredients of Lianhua
Qingwen. The broad-spectrum activity of Lianhua Qingwen is
through the mitogen-activated protein kinase and Hepatitis B
signaling pathways (Wang et al., 2020b).
Existing Drugs
The antiviral agents (remdesivir, favipiravir) (Martinez, 2020;
Wang et al., 2020c), antimalarials (chloroquine,
hydroxychloroquine) (Xu et al., 2020), and the combination of
(lopinavir/ritonavir) (Lu, 2020; Zhang et al., 2020a) have shown
promising results and are also in the various stages of attempt for
the treatment of COVID-19 (Figure 1) (Amawi et al., 2020; Busse
et al., 2020). Remdesivir has shown inhibitor activity against
SARS-CoV as well as MERS-CoV, and it is already under clinical
trial for the treatment of Ebolavirus and COVID-19 infection
(Kotta et al., 2020). Recently, the SARS-CoV-2 controlling
activity of remdesivir in in-vitro has been reported (Wang
et al., 2020c). The preliminary clinical trial data has shown
faster recovery from COVID-19 when the patients with
moderate to severe symptoms are treated with remdesivir and
other supportive therapy (Malin et al., 2020). Chloroquine
reduced the viral load in several studies and
hydroxychloroquine has shown short-term efficacy in COVID-
19 patients (Zhang et al., 2020a). A clinical trial for the
combination of lopinavir-ritonavir has been conducted with
hospitalized adults of COVID-19 patients. The combined
medication of lopinavir-ritonavir (400:100 mg) has been given
twice a day for a period of 14-day. Gastrointestinal adverse effects
were observed among the treatment groups. A significant
therapeutic improvement was not observed with the lopinavir-
ritonavir combination and the trial has been stopped (Cao et al.,
2020).
Monoclonal Antibodies
The monoclonal antibodies provide passive immunity to the
inhibition of viral entry into the host by various processes like
antibody-dependent cellular cytotoxicity, phagocytosis, and
antibody-mediated neutralization. Recently, the monoclonal
antibodies 1) the combination of casirivimab (REGN10933)-
imdevimab (REGN10987) 2) the combination of
bamlanivimab (LY-CoV555)-etesevimab were authorized for
the emergency use in the treatment of COVID-19 from mild
to severe cases by FDA. The combination of bamlanivimab-
etesevimab has reduced the hospitalization of COVID-19
patients. Casirivimab-imdevimab combination has been
rationalized to control the mutated SARS-CoV-2.
Bamlanivimab targets the spike protein of SARS-CoV-2 to
prevent viral entry (Wolf et al., 2021). Tocilizumab is used for
the handling of rheumatic diseases. It is a type of recombinant IL-
6 human monoclonal antibody. Tocilizumab along with other
antiviral agents has shown significant improvement among
COVID-19 patients in the retrospective study (Zhang et al.,
2020a). However, the safety, efficacy, and validity of all these
medications against COVID-19 have not yet been confirmed with
the extensive clinical trial experiments.
THERAPEUTIC TARGETS
The size of SARS-CoV-2 is ∼120 nm in diameter (Lim et al.,
2016). The molecular targets for the inhibition of entry of SARS-
CoV-2 are 1) M-protein (main protein-Mpro) 2) S-protein
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(spike protein) 3) E-protein (envelope protein) 4) N-protein
(nucleocapsid protein) (Figure 2). All these proteins are
required for the production of complete viral particles
(Table 1). The inhibition of these viral proteins affects the
virus’s life cycle. Several crystal structures for these therapeutic
targets are obtainable from the protein data bank (PDB)
(Figure 3). The understanding of the structural features and
mechanistic functions of these molecular targets sets the stage to
discover a newer medication for the treatment of COVID-19
infection.
FIGURE 1 | The reported drug molecules showing promising results against COVID-19.
FIGURE 2 | The representation of therapeutic targets for COVID-19 in SARS-CoV-2.
TABLE 1 | The structures and functions of therapeutic targets of COVID-19.
No Target proteins Functions PDB IDs Resolution (Ref.)
1 Main protease (Mpro) Viral replication and transcription 7BUY 1.60 Å Jin et al. (2020b)
2 Spike protein (S-protein) Viral entry into the host cell organ 6VXX 2.80 Å Walls et al. (2020)
3 Envelope protein (E-protein) Formation of viral envelope and assembly 7K3G 2.10 Å Mandala et al. (2020)
4 Nucleocapsid protein (N-protein) Formation of nucleocapsid 6YUN 1.45 Å Zinzula et al. (2021)
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Main Protease
Main protease (Mpro) is the type of papain-like protease and is involved
in the maturation of non-structural protein. The replicating gene of
SARS-CoV-2 encodes two polyproteins named PP1a and PP1ab.
These polyproteins are processed for proteolytic cleavage by Mpro
to release functional protein. The functional proteins play a crucial role
in viral replication and transcription. Therefore, the inhibition of Mpro
is an attractive strategy for the treatment of COVID-19. The estimated
molecular mass of Mpro is ∼33.8 kDa in mass spectrometry. The
substrate-binding pocket of SARS-CoV-2 constitutes amino acids
Cys145 and His41. The sulfhydryl group of Cys145 reacts with the
electrophilic fragment of the substrate leading to form a covalent bond.
This covalent modification results in the inhibition of Mpro. Six
compounds (Ebselen, Disulfiram, Tideglusib, Carmofur, Shikonin,
and PX-12) were reported to inhibit Mpro (Table 1) (Jin et al., 2020b).
Spike Protein
Spike protein (S-protein) is present on the surface structure of
coronavirus that helps for the viral entry into the host cell by
binding through angiotensin-converting enzyme 2 (ACE-2)
receptor (Jin et al., 2020a). Therefore, ACE-2 could act as an
RBD for SARS-CoV-2. The RBD of SARS-CoV-2 spike protein
has been targeted to competitively inhibit viral entry. The spike
protein (∼180–200 kDa) is present in the glycosylated form. The
N-terminus part of the spike protein is positioned at the outside of
the viral surface whereas the C-terminus is located at the
intramembrane space. The composition of spike protein includes
S1-subunit and S2-subunit with a cleavage site for protease between
S1 and S2. The S1-subunit of spike proteinmakes initial contact with
the host cell ACE-2 receptor for the initial viral entry. The receptor
specificity is achieved from the S1-subunit that forms the RBD. The
S2-subunit of the SARS-CoV-2 comprises fusion protein, heptad
regions (HR1 and HR2), transmembrane, and a cytoplasmic
domain. The S2-subunit is responsible for membrane fusion
(Table 1) (Jin et al., 2020a; Walls et al., 2020)
Envelope Protein
Envelope protein (E-protein) is a small-membrane protein that is
responsible for the pathogenesis, formation of the viral envelope,
viral assembly, viral budding, and interaction with the host cell.
The E-protein forms a homopentameric ion channel known as
viroporin. The hydrophobic nature of the transmembrane
domain of E-protein oligomerizes to form an ion channel.
This ion channel helps the virus to interact with other viral
proteins as well as host cell proteins. The absence of E-protein
coronavirus has shown reduced viral infection. Therefore, the
lack of E-protein virus aids vaccine development. The envelope
protein is highly expressed in the infected cells during the
replication process and promotes the formation of the viral
envelope. The molecular mass of E-protein is ∼8.4–12 kDa
comprising 76–109 amino acid residues. The structure of
E-protein constitutes hydrophilic terminus (7–12 amino acids),
carboxy terminus, and hydrophobic transmembrane domain (25
amino acids) (Table 1) (Mandala et al., 2020).
Nucleocapsid Protein
Nucleocapsid protein (N-protein) encapsulates the RNA genome of
the virus. It is involved in the formation of the nucleocapsid.N-protein
also participates in viral replication and viral infection (Table 1). The
co-expression of N-protein enhances the production of the viruses
further. The main function of N-protein is oligomerization and
packaging of the single-stranded viral RNA genome. Moreover, it
is highly immunogenic and therefore, it is an attractive target protein
for the treatment ofCOVID-19. Themolecularmass ofN-protein is in
the range of 37.7–51.5 kDs. It is organized as an N-terminal domain,
intrinsically disordered domain, and C-terminal domain. The N-
terminal domain and-C-terminal domain are responsible for genome
packing whereas the intrinsically disordered domain is responsible for
the RNA binding activity (Zinzula et al., 2021).
RESEARCH PROGRESS AND STRATEGIES
FOR THE DEVELOPMENT OF NEWER
MEDICATIONS AGAINST COVID-19
The immune response against the vaccine remains unclear. The
administration of neutralizing antibodies has been shown to halt
FIGURE 3 | Three-dimensional structures of (A)main protease (PDB ID:
7BUY) (B) spike protein (PDB ID: 6VXX) (C) envelope protein (PDB ID: 7K3G)
(D) nucleocapsid protein (PDB ID: 6YUN) (The protein is blue at the N-terminus
and red at the C-terminus).
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the disease progression. However, the possibilities of re-infection
cannot be ignored. At present, few vaccines are approved; and few
more vaccines, inhibitors, antibodies, immunity enhancers, etc.,
are at various stages of development. However, major efforts have
been put to develop peptide-based drug candidates to treat
COVID-19 infection (Vanpatten et al., 2020). Moreover, the
computational studies to explore the mechanistic behavior of
the therapeutic targets of SARS-CoV-2 are also under progress.
Vaccines
In many cases, mRNA-based vaccines have been proposed for
infectious diseases and cancers. Recently, a thermostable mRNA
vaccine candidate known as ARCoV has been developed by
Zhang et al for the management of the COVID-19 pandemic.
The vaccine is a lipid nanoparticle encapsulated type that encodes
the RBD of SARS-CoV-2. The intramuscular vaccination of
ARCoV produced neutralizing antibodies in mice and other
models. Two doses of vaccination have shown complete
protection and the vaccine was found to be stable for a week
at room temperature. ARCoV vaccine is in the phase-1 stage of
clinical trial evaluation (Table 2) (Zhang et al., 2020b).
The mRNA-1273 vaccine has been expressed from the spike
trimer of SARS-CoV-2. The mRNA-1273 vaccine induces the
neutralizing antibody and triggers CD8 T cell responses against
TABLE 2 | Research progress on the therapeutic targets of SARS-CoV-2 to treat the COVID-19 infection.
No Title of the work Targets Outcome Biological screening Ref
Vaccines
1 A thermostable mRNA vaccine against
COVID-19




2 SARS-CoV-2 mRNA vaccine development
enabled by prototype pathogen
preparedness
Spike protein mRNA-1273 vaccine It has reduced the viral load
100 fold at the
concentration of 0.1 µg
Corbett et al.
(2020)
3 Design of a multiepitope-based peptide
vaccine against the E Protein of human
COVID-19: An immunoinformatics approach
E-protein YVYSRVKNL, SLVKPSFYV, and
LAILTALRL
--- Abdelmageed et al.
(2020)
Inhibitors
4 Peptide antidotes to SARS-CoV-2
(COVID-19)






5 Computational design of ACE2-based
peptide inhibitors of SARS-CoV-2
RBD Inhibitors-2, inhibitor-3, and inhibitor-4 --- Han and Král,
(2020)
6 Design of potent membrane fusion inhibitors
against SARS-CoV-2, an emerging
coronavirus with high fusogenic activity
Spike protein Lipopeptide (IPB02) Dual split-protein based
fusion cell-cell assay
(0.025 μM)
Zhu et al. (2020b)
7 Peptide-like and small-molecule inhibitors
against COVID-19
Mpro Cobicistat, ritonavir, lopinavir, and
darunavir
--- Pant et al. (2020)
Antibodies
8 A human monoclonal antibody blocking
SARS-CoV-2 infection
Spike protein 47D11 antibody IC50 value: 0.57 μg/ml Wang et al. (2020d)
9 Potent binding of 2019 novel coronavirus
spike protein by a SARS coronavirus specific
human monoclonal antibody
Spike protein Monoclonal antibody (CR3022) KD value: 6.3 nM Tian et al. (2020)
Immunity enhancers or modulators
10 The potential of antimicrobial peptides as an
antiviral therapy against COVID-19
--- Lactoferrin --- Elnagdy and
Alkhazindar, (2020)
11 Type 1 interferons as a potential treatment
against COVID-19
--- Type 1 interferons --- Sallard et al. (2020)
Miscellaneous
12 SARS-CoV and SARS-CoV-2 main protease
residue interaction networks change when
bound to inhibitor N3
Mpro Identified the conformational changes
in one cluster and four residues (131,
175, 182, and 185)
--- Griffin (2020)
13 In silico discovery of candidate drugs against
covid-19
--- Identified 36-drugs candidates as
effective agents against COVID-19
--- Cava et al. (2020)
14 Structural basis of SARS-CoV-2 3CL pro and





Identified 9-hit molecules for the
management of COVID-19
--- Tahir ul Qamar
et al. (2020)
15 Computational screening of antagonists
against the SARS-CoV-2 (COVID-19)
coronavirus by molecular docking
Main protease Luteolin has been suggested as a hit
molecule for the specific binding with
SARS-CoV-2 main protease
--- Yu et al. (2020b)
Frontiers in Molecular Biosciences | www.frontiersin.org July 2021 | Volume 8 | Article 6482326
Ramesh et al. Discovery of Newer Medications Against the COVID-19
SARS-CoV-2 in mice. The 0.1 µg concentration of mRNA-1273
reduced the viral load by ∼100 fold and 1 µg of mRNA-1273 was
observed to be effective for 3 months to protect from viral
replication. Currently, the mRNA-1273 vaccine is in the
phase-2 stage of clinical trial and is focused on the phase-3
clinical evaluation (Table 2) (Corbett et al., 2020).
Multiepitope-based peptide vaccine was designed from an
immunoinformatics approach and comparative genomic
approach for the management of COVID-19 by Abdelmageed
et al. The envelope protein of novel coronavirus was used as the
immunogenic target to design the T-cell epitope-based peptide
vaccine. The gene bank files were obtained from NCBI. The
binding affinity of the peptides with major histocompatibility
complex classes (MHC-I and MHC-II) was estimated from
molecular docking in AutoDock. The study concluded
YVYSRVKNL, SLVKPSFYV, and LAILTALRL as potential
peptides for the vaccine design against COVID-19 (Table 2)
(Abdelmageed et al., 2020).
Promising results from the clinical trials of the BNT162b2
(Pfizer/BioNTech) and ChAdOx1 nCoV-19 (Oxford/
AstraZeneca) vaccines were obtained. BNT162b2 (Pfizer/
BioNTech) is a nucleoside-modified mRNA vaccine. It
encodes the spike protein of SARS-CoV-2. The clinical trial
of BNT162b2 has begun in April-2020 and it has been tested
on 40,000 people. The phase-1 and phase-2 trials reported the
safety and efficacy of this vaccine. The phase-3 clinical trial
has reported the safety, efficacy, tolerability, and
immunogenicity at the mild dose level among the different
age groups. Moreover, the vaccination of BNT162b2
(tozinameran) has shown 52.4% efficacy after the
administration of the first dose and before the
administration of the second dose. After the second dose of
vaccination, 94.8% efficacy was observed against COVID-19.
Therefore, it has been authorized by the regulatory authority
for the emergency use (Oliver et al., 2020).
Several viral-vector-based vaccines are under the various
stages of clinical trials (Bezbaruah et al., 2021).
ChAdOx1 nCoV-19 vaccine has been developed by Oxford
University and AstraZeneca against COVID-19.
ChAdOx1 nCoV-19 (AZD1222) is a chimpanzee adenovirus
vectored vaccine composed of the coding sequence of the
spike protein. The results of phase-3 clinical trials were
obtained in November-2020. The overall efficacy of this
vaccine is 70.4%. It has been approved by various medicine
agencies like the European medicines Agency, Australian
Therapeutic Goods Administration, etc., Moreover, the vaccine
has closer efficacy as with other vaccines in the low-dose regimen.
ChAdOx1 nCoV-19 vaccine may also provide maximum
protection against COVID-19 (Knoll and Wonodi, 2021).
Inhibitors
Watson et al demonstrated the role of peptide antidotes (SARS-
BLOCK™ - a synthetic peptide scaffolds) to SARS-CoV-2
mediated COVID-19 infection. SARS-BLOCK™ inhibits the
RBD of the S1-part of spike protein that binds to ACE-2, the
S1-subunit is essential for the SARS-CoV-2 to enter into the host
cell through ACE-2. These peptide scaffolds were designed by
mimicking the RBD of spike protein using computational
technologies like SWISS-MODEL, PDBePISA, and RaptorX.
Biomimetic technology has also been applied to enhance the
stability of these designed peptides. Then, the peptides were
synthesized by solid-phase peptide synthesis technology. The
synthetic peptides were characterized for their binding to
ACE-2 in biolayer interferometry. The peptides have shown
single-micromolar affinities to ACE-2. Therefore, it may serve
as a novel prophylactics as well as immune stimulants against
COVID-19 (Table 2) (Watson et al., 2020).
The peptide inhibitors were designed to block the RBD of
SARS-CoV-2 based on ACE-2. The conformation and stability of
the peptides were analyzed by molecular dynamics in NAMD
software. The peptides which use α1,2 helices have shown bent
shape in simulation studies. This conformation matches with the
RBD domain of SARS-CoV-2. The amino acid residues of ACE-2,
i.e., 24(Q), 27(T), 30(D), 31(K), 34(H), 35(E), 37(E), 38(D), 41(Y),
and 42(Q) of α1; 82(M) of α2; 353(K), 354(G), 355(D), and 357(R)
of the linkering unit between β3 and β4 were found as interacting
residues with RBD. The study designed four types of inhibitors
based on the amino acid residues 1) inhibitor-1 (α1-helix), 2)
inhibitor-2 (α1-and α2-helices), 3) inhibitor-3 (α1, α2, and β3, β4)
and 4) inhibitor-4 (same as inhibitor-3 with a different linker). The
approach proposed these inhibitors as efficient therapeutic
candidates for COVID-19 (Table 2) (Han and Král, 2020).
The entry of SARS-CoV-2 into the human occurs through the
fusogenic action of the spike protein of the virus with the human
ACE-2 receptor. Therefore, the membrane fusion inhibitors
(IPB01and IPB02) with higher fusogenic activity have been
designed against SARS-CoV-2 by Zhu et al. The fusogenic
inhibitor IPB02 has been designed using the sequence of HR2
in spike protein. IPB02 is a lipopeptide that has shown significant
thermal stability and binding affinity. The synthetic peptide IB02
exhibited cell-fusion inhibition at the level of 0.025 μM in a dual
split-protein-based fusion cell-cell assay. The study has described
the entry pathway of SARS-CoV-2 into the host and the design of
fusion inhibitors (Table 2) (Zhu et al., 2020b).
Peptide-like and small molecules were predicted as potential
inhibitors for COVID-19 using in-silico methods from the
databases of CHEMBL, ZINC, FDA-approved drugs, and
effective molecules under clinical trials. The study employed
molecular docking, molecular dynamics analysis using the
crystal structures (PDB ID: 6Y2F, PDB ID: 6W63) to identify
the potential candidates to inhibit Mpro. The potency of the hit
molecules was analyzed based on docking scores and binding
affinities. Cobicistat, ritonavir, lopinavir, and darunavir were
predicted as potential inhibitors for Mpro. However, the
experimental validation of the computational results was not
documented (Table 2) (Pant et al., 2020).
Antibodies
The first human monoclonal antibody to block SARS-CoV and
SARS-CoV-2 infection in cell culture has been reported. The
recombinantly expressed 47D11 antibody has shown cross-
neutralizing activity against SARS-CoV-2. It binds with the
spike protein of SARS-CoV-2 and its binding was
characterized by immunofluorescence microscopy. The
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antibody can also be used for the detection of antigens (Table 2)
(Wang et al., 2020d).
A SARS-specific human monoclonal antibody for binding
with novel coronavirus spike protein has been reported. The
antibody was obtained from the bloodstream of the SARS patient.
The monoclonal antibody (CR3022) has shown potent binding
with RBD of SARS-CoV-2 (KD value: 6.3 nM). The other SARS-
specific neutralizing antibodies (m396, CR3014) did not show a
significant binding affinity with the spike protein of novel
coronavirus. Therefore, the study indicated the difference
between the RBD of SARS-CoV and SARS-nCoV. The study
suggested that the monoclonal antibody (CR3022) may be served
alone or along with other therapeutics to stop the COVID-19
infection (Table 2) (Tian et al., 2020).
Immunity Enhancers or Modulators
The antimicrobial peptides possess a wide range of antiviral activities
from human to animal viruses. The antimicrobial peptide molecules
are small in size consisting of 10–100 amino acids. These are
amphiphilic with a cation charge that helps to attach to viruses.
Lactoferrin is one of the antimicrobial peptides that has been
proposed as an immunity enhancer by Elnagdy et al. Since
lactoferrin has shown immunity enhancement against viral
infection, it has been proposed as a promising candidate for the
treatment of COVID-19. Lactoferrin is usually present in breast milk
and the mucosal layer (Table 2) (Elnagdy and Alkhazindar, 2020).
Type-1 interferons are mainly secreted by plasmacytoid
dendritic cells when it identifies the viral components. Type-1
interferons have also shown a wide-ranging of antiviral activities
and it is under clinical trial against the MERS-CoV. INF-1 is the
first cytokine produced during the initial pathogenesis of viral
infection. It interferes with the viral replication process and
promotes adaptive immunity. Based on the structural
resemblance of MERS-CoV with SARS-CoV, the possibilities
of type-1 interferon for the handling of COVID-19 have also
been proposed (Table 2) (Sallard et al., 2020).
Miscellaneous
The residue interaction networks change in the Mpro of SARS-CoV
and SARS-CoV-2 due to inhibitor binding has been studied by
Griffin et al. The network clustering was performed with and
without inhibitor (N3) in Mpro of SARS-CoV and SARS-CoV-2.
The network change among the cluster of residues (17, 18, 30–33, 70,
95, 98, 103, 117, 122, and 177) has been observed when the inhibitor
N3 binds with Mpro. Moreover, the amino acid residues (131, 175,
182, and 185) were found to be responsible for the conformational
changes. The study revealed the conformational changes of Mpro
when binding with the inhibitor and provided the structural insights
to develop an inhibitor for Mpro (Table 2) (Griffin, 2020).
Cava and co-workers carried out in-silico discovery to
investigate the molecular mechanism of ACE-2 with COVID-
19 and found few candidate drugs against COVID-19. The study
reported 36 drugs including nimesulide, fluticasone propionate,
thiabendazole, photofrin, didanosine, and flutamide as potential
candidates for COVID-19 from the gene expression analysis.
However, the experimental validation of the results has not been
conveyed (Table 2) (Cava et al., 2020).
The replication process of SARS-CoV-2 in the life cycle is
mainly controlled by 3-chymotrypsin-like cysteine protease
(3CLpro). Therefore, 3CLpro has been recognized as a
therapeutic target for COVID-19. Qamar et al constructed a
3D structural model for 3CLpro from the sequence analysis and
studied the structural basis of 3CLpro. Then, the in-silico screening
was carried out on the library of medicinal plant compounds
based on molecular docking, ADME prediction, and molecular
dynamics. The approach results in the identification of nine hit
molecules that could serve as potential therapeutic candidates for
COVID-19 (Table 2) (Tahir ul Qamar et al., 2020).
Ribavirin, remdesivir, chloroquine, and luteolin were
computationally screened using AutoDock software to study
the binding mechanism toward SARS-CoV-2. Luteolin and
chloroquine have shown substantial binding affinity at the
binding site of SARS-CoV-2 main protease. Luteolin has
shown the binding interaction with Gln189, Leu4, Asn142,
Thr26, Met49, and Val3 residues. These interactions were
found to be as similar as N3 which is a bound ligand of the
main protease. Luteolin has been projected as a possible hit
molecule for the specific binding with SARS-CoV-2 main
protease (Table 2) (Yu et al., 2020b).
CONCLUSION
There is a serious requirement to develop newer drugs, vaccines,
and therapy for the treatment of COVID-19. The approaches based
on traditional drug discovery are slow, time-consuming, and costly.
Therefore, traditional drug discovery approaches may not be an
appropriate method to discover newer medications during the
outbreak of COVID-19. The computer-aided drug discovery
approaches intending to repurpose the existing and approved
drugs or the development of peptide-based drugs may provide a
rapid solution against COVID-19. Although, the peptide-based
drug candidates are preferable to develop in terms of time, cost,
specificity, and affinity; the proteolytic instability of peptide-based
drugs would be a major concern in the development processes.
Therefore, the approaches based on drug-repurposing, and
development of peptidomimetic candidates may be effective to
discover newer medications during the COVID-19 outbreak. The
information provided in this article may shed a light to discover
newer medications to eradicate the COVID-19.
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